Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol

Diabetes Technology and Therapeutics

Volumn 20, Issue 9, 2018, Pages 572-575

  Garg, Satish K ^a,b   Peters, Anne L ^c   Buse, John B ^d   Danne, Thomas ^e  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO DENVER   (United States)

^c UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^e HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

SODIUM GLUCOSE COTRANSPORTER 1 INHIBITOR; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SODIUM GLUCOSE COTRANSPORTER INHIBITOR;

BODY WEIGHT; CONCURRENT INFECTION; DIABETIC KETOACIDOSIS; DIABETIC PATIENT; GENE EXPRESSION; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; KIDNEY TUBULE ABSORPTION; PANCREAS ISLET ALPHA CELL; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SODIUM ABSORPTION; CHEMICALLY INDUCED; CLINICAL PROTOCOL; COMPLICATION;

CLINICAL PROTOCOLS; DIABETES MELLITUS, TYPE 1; DIABETIC KETOACIDOSIS; HUMANS; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85052617373     PISSN: 15209156     EISSN: 15578593     Source Type: Journal    
DOI: 10.1089/dia.2018.0246     Document Type: Review

References (27)

1. Umpierrez G, Korytkowski M: Diabetic emergencies-ketoacidosis, hyperglycaemic hyperosmolar state and hy-poglycaemia. Nat Rev Endocrinol 2016;12:222-232.
2. Kitabchi AE, Umpierrez GE, Miles JM, Fisher JN: Hy-perglycemic crises in adult patients with diabetes. Diabetes Care 2009;32:1335-1343.
3. Dhatariya K, Savage M: The management of diabetic ke-toacidosis in adults. 2nd ed. Solihull, West Midlands, UK: Joint British Diabetes Societies Inpatient Care Group, 2013.
4. Centers for Disease Control and Prevention: National Diabetes Statistics Report. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services, 2017.
5. Miller KM, Foster NC, Beck RW, et al.: Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry. Diabetes Care 2015;38:971-978.
6. Realsen J, Goettle H, Chase HP: Morbidity and mortality of diabetic ketoacidosis with and without insulin pump care. Diabetes Technol Ther 2012;14:1149-1154.
7. Tamborlane WV, Sikes KA: Insulin therapy in children and adolescents. Endocrinol Metab Clin North Am 2012;41: 145-160.
8. Hanas R, Lindgren F, Lindblad B: A 2-yr national population study of pediatric ketoacidosis in Sweden: predisposing conditions and insulin pump use. Pediatr Diabetes 2009;10:33-37.
9. Taylor SI, Blau JE, Rother KI: SGLT2 inhibitors may predispose to ketoacidosis. J Clin Endocrinol Metab 2015; 100:2849-2852.
10. Barski L, Brandstaetter E, Sagy I, Jotkowitz A: Basal insulin for the management of diabetic ketoacidosis. Eur J Intern Med 2018;47:14-16.
11. Thalange N, Deeb L, Iotova V, et al.: Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes. Pediatr Diabetes 2015;16:164-176.
12. Peters AL, Buschur EO, Buse JB, et al.: Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care 2015;38:1687-1693.
13. Fralick M, Schneeweiss S, Patorno E: Risk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor. N Engl J Med 2017;376:2300-2302.
14. Buse JB, Garg SK, Rosenstock J, et al.: Sotagliflozin in combination with optimized insulin therapy in adults with type 1 diabetes: the North American inTandem1 study. Diabetes Care 2018, doi: 10.2337/dc18-0343 [Epub ahead of print]
15. Garg SK, Henry RR, Banks P, et al.: Effects of sotagliflozin added to insulin in patients with type 1 diabetes. N Engl J Med 2017;377:2337-2348.
16. Danne T, Cariou B, Banks P, et al.: A1C and hypoglycemia reduction at 24 and 52 weeks with sotagliflozin in combination with insulin in adults with type 1 diabetes: the European inTandem2 study. Diabetes Care 2018, doi: 10.2337/dc18-0342. [Epub ahead of print]
17. Dandona P, Mathieu C, Phillip M, et al.: Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 2017;5:864-876.
18. Mathieu C, Dandona P, Gillard P, et al.: Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 Study): 24-week results from a randomized controlled trial. Diabetes Care 2018, doi: 10.2337/dc18-0623. [Epub ahead of print]
19. Garg SK, Strumph P: Effects of sotagliflozin added to insulin in type 1 diabetes. N Engl J Med 2018;378:967-968.
20. Yamada T, Shojima N, Noma H, et al.: Sodium-glucose co-transporter-2 inhibitors as add-on therapy to insulin for type 1 diabetes mellitus: systematic review and meta-analysis of randomized controlled trials. Diabetes Obes Metab 2018; 20:1755-1761.
21. Merovci A, Solis-Herrera C, Daniele G, et al.: Dapagli-flozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest 2014;124: 509-514.
22. Ferrannini E, Muscelli E, Frascerra S, et al.: Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. J Clin Invest 2014;124:499-508.
23. Bonner C, Kerr-Conte J, Gmyr V, et al.: Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med 2015;21: 512-517.
24. PRNewswire: Boehringer Ingelheim and Lilly announce positive top-line Phase III data results for empagliflozin as adjunct to insulin in type 1 diabetes. Indianapolis, IN: Eli Lilly and Company, 2018.
25. Handelsman Y, Henry RR, Bloomgarden ZT, et al.: American Association of Clinical Endocrinologists and American College of Endocrinology position statement on the association of SGLT-2 inhibitors and diabetic ketoaci-dosis. Endocr Pract 2016;22:753-762.
26. Pieber TR, Famulla S, Eilbracht J, et al.: Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1). Diabetes Obes Metab 2015;17:928-935.
27. Kitabchi AE, Fisher JN, Murphy MB, Rumbak MJ: Diabetic ketoacidosis and the hyperglycemic hyperosmolar nonketotic state. In: Kahn CR, Weir GC, eds. Joslin's Diabetes Mellitus. 13th ed. Philadelphia: Lea & Febiger, 1994:738-770.